| 1 |
Arrabal Polo MÁ, Melgarejo Segura MT, Yáñez Castillo Y, Morales Martínez A, Pareja Vílchez M, Arrabal Martín M. Adjuvant intravesical treatment in patients with intermediate and high-risk non-muscle-invasive bladder cancer with BCG versus MMC applied with COMBAT or EMDA. Results of a prospective study. J Cancer Res Clin Oncol 2023. [PMID: 36952006 DOI: 10.1007/s00432-023-04688-0] [Reference Citation Analysis]
|
| 2 |
Lin PT, Hung WK, Chang YH, Hsieh ML, Liu CY, Huang LK, Chu YC, Kan HC, Lin PH, Yu KJ, Chuang CK, Wu CT, Pang ST, Shao IH. Replacement Instead of Discontinuation of Bacillus Calmette-Guérin Instillation in Non-Muscle-Invasive Bladder Cancer. Cancers (Basel) 2023;15. [PMID: 36831686 DOI: 10.3390/cancers15041345] [Reference Citation Analysis]
|
| 3 |
Tan WS, Mustard C, Kelly JD; HIVEC-II trial team. Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak's Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003. Eur Urol 2023;83:e48-9. [PMID: 36456403 DOI: 10.1016/j.eururo.2022.11.006] [Reference Citation Analysis]
|
| 4 |
Du Z, Yin H, Zhao S, Ma Y, Sun Z, Dong B, Zhu M, Zhu C, Peng J, Yang T. Case report: Gemcitabine intravesical hyperthermic infusion combined with tislelizumab in muscle invasive bladder urothelium carcinoma. Front Oncol 2022;12:1062655. [PMID: 36620538 DOI: 10.3389/fonc.2022.1062655] [Reference Citation Analysis]
|
| 5 |
Jing L, Wenjian C, Meimei Z, Yanfei C, Xuejin Z, Bin W. Development and investigation of a novel device with gemcitabine for hyperthermic intravesical chemotherapy. Int J Hyperthermia 2023;40:2129103. [PMID: 36535955 DOI: 10.1080/02656736.2022.2129103] [Reference Citation Analysis]
|
| 6 |
Zhang P, Ding Y. Novel Therapeutic Strategies for BCG-unresponsive Non-muscle Invasive Bladder Cancer. ann urol oncol 2022. [DOI: 10.32948/auo.2022.11.27] [Reference Citation Analysis]
|
| 7 |
Zhou W, Liu J, Mao D, Hu C, Gao D. The clinical efficacy and safety of equipment-assisted intravesical instillation of mitomycin C after transurethral resection of bladder tumour in patients with nonmuscular invasive bladder cancer: A meta-analysis. PLoS One 2022;17:e0276453. [PMID: 36269742 DOI: 10.1371/journal.pone.0276453] [Reference Citation Analysis]
|
| 8 |
Tan WP, Bello AP, Garcia Alvarez C, Guerrero-ramos F, González-padilla DA, Nzeh C, Manuel de la Morena J, de Torres IGV, Hendricksen K, Díaz Goizueta FJ, Del Alamo FJ, Chiancone F, Fedelini P, Poggio M, Porpiglia F, Gonzalo Rodríguez VC, Torres JM, Wilby D, Robinson R, Sousa-escandón A, Mata JL, Moreno JLP, Molina FD, Semino MAA, Stemberger AT, Calleja-escudero J, Redorta JP, Tan WS. A Multicenter Study of 2-year Outcomes Following Hyperthermia Therapy with Mitomycin C in Treating Non-Muscle Invasive Bladder Cancer: HIVEC-E. BLC 2022. [DOI: 10.3233/blc-220026] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 9 |
Tan WS, Prendergast A, Ackerman C, Yogeswaran Y, Cresswell J, Mariappan P, Phull J, Hunter-Campbell P, Lazarowicz H, Mishra V, Rane A, Davies M, Warburton H, Cooke P, Mostafid H, Wilby D, Mills R, Issa R, Kelly JD. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol 2022:S0302-2838(22)02552-0. [PMID: 35999119 DOI: 10.1016/j.eururo.2022.08.003] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 10 |
Wang J, Yang P, Hou D, Yan Y, Yue K, Zhong W, Xiao T, Wu X, Wang Z, Wu P, Wang L, Wang H, Xu W. Bacteria-inspired transformable nanoparticle targets and covers residual tumor against bladder cancer recurrence. Nano Today 2022;45:101551. [DOI: 10.1016/j.nantod.2022.101551] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 11 |
González-padilla DA, Subiela JD, González-díaz A, Hernández-arroyo M, García-rojo E, Aumatell J, Burgos Revilla J, Rodríguez-antolín A, Guerrero-ramos F. Mitomycin C allergy after passive and device-assisted hyperthermia for non-muscle invasive bladder cancer treatment: A retrospective cohort from a high-volume center. Urologic Oncology: Seminars and Original Investigations 2022;40:345.e19-345.e23. [DOI: 10.1016/j.urolonc.2022.02.018] [Reference Citation Analysis]
|
| 12 |
Vartolomei MD, Ferro M, Roth B, Teoh JY, Gontero P, Shariat SF. Device-assisted intravesical chemotherapy treatment for nonmuscle invasive bladder cancer: 2022 update. Curr Opin Urol 2022. [PMID: 35749398 DOI: 10.1097/MOU.0000000000001010] [Reference Citation Analysis]
|
| 13 |
Hou DY, Zhang NY, Wang MD, Xu SX, Wang ZJ, Hu XJ, Lv GT, Wang JQ, Wu XH, Wang L, Cheng DB, Wang H, Xu W. In Situ Constructed Nano-Drug Depots through Intracellular Hydrolytic Condensation for Chemotherapy of Bladder Cancer. Angew Chem Int Ed Engl 2022;61:e202116893. [PMID: 35181975 DOI: 10.1002/anie.202116893] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 14 |
Teoh JY, Kamat AM, Black PC, Grivas P, Shariat SF, Babjuk M. Recurrence mechanisms of non-muscle-invasive bladder cancer - a clinical perspective. Nat Rev Urol 2022. [PMID: 35361927 DOI: 10.1038/s41585-022-00578-1] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 15 |
Kostyev F, Bondar O, Chystiakov R, Lysenko V, Stavnychyi O, Varbanets V. The impact of different adjuvant intravesical therapy methods on tumor biology in patients with high-risk non-muscle-invasive bladder cancer. Cent European J Urol 2021;74:496-502. [PMID: 35083068 DOI: 10.5173/ceju.2021.0122] [Reference Citation Analysis]
|
| 16 |
Zhao H, Chan VW, Castellani D, Chan EO, Ong WLK, Peng Q, Moschini M, Krajewski W, Pradere B, Ng CF, Enikeev D, Vasdev N, Ekin G, Sousa A, Leon J, Guerrero-Ramos F, Tan WS, Kelly J, Shariat SF, Witjes JA, Teoh JY. Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis. Front Surg 2021;8:775527. [PMID: 34888347 DOI: 10.3389/fsurg.2021.775527] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 17 |
Palugan L, Cerea M, Cirilli M, Moutaharrik S, Maroni A, Zema L, Melocchi A, Uboldi M, Filippin I, Foppoli A, Gazzaniga A. Intravesical drug delivery approaches for improved therapy of urinary bladder diseases. Int J Pharm X 2021;3:100100. [PMID: 34765967 DOI: 10.1016/j.ijpx.2021.100100] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 18 |
Thyavihally YB, Waigankar SS, Dev P, Asari A, Pednekar AP, Athikari N, Raut A, Khandekar A, Badlani N. Comparing adverse effects, short term outcomes, and cost implications of hyperthermic intravesical chemotherapy with Mitomycin-C and intravesical bacillus Calmette-Guerin instillation (Moscow-I strain) in the management of intermediate and high-risk nonmuscle invasive bladder cancer. Urol Ann 2021;13:424-30. [PMID: 34759657 DOI: 10.4103/UA.UA_139_20] [Reference Citation Analysis]
|
| 19 |
Brummelhuis ISG, Simons M, Lindner LH, Kort S, de Jong S, Hossann M, Witjes JA, Oosterwijk E. DPPG2-based thermosensitive liposomes as drug delivery system for effective muscle-invasive bladder cancer treatment in vivo. Int J Hyperthermia 2021;38:1415-24. [PMID: 34581259 DOI: 10.1080/02656736.2021.1983038] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 20 |
Sun J, Wei X, You J, Yue W, Ouyang J, Ling Z, Hou J. STC1 is a Novel Biomarker Associated with Immune Characteristics and Prognosis of Bladder Cancer. Int J Gen Med 2021;14:5505-16. [PMID: 34539184 DOI: 10.2147/IJGM.S329723] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 21 |
Pijpers OM, Hendricksen K, Mostafid H, de Jong FC, Rosier M, Mayor N, de Jong JJ, Boormans JL. Long-term efficacy of hyperthermic intravesical chemotherapy for BCG-unresponsive non-muscle invasive bladder cancer. Urol Oncol 2021:S1078-1439(21)00337-9. [PMID: 34470725 DOI: 10.1016/j.urolonc.2021.07.019] [Cited by in Crossref: 6] [Cited by in F6Publishing: 8] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 22 |
Che X, Zhan J, Zhao F, Zhong Z, Chen M, Han R, Wang Y. Oridonin Promotes Apoptosis and Restrains the Viability and Migration of Bladder Cancer by Impeding TRPM7 Expression via the ERK and AKT Signaling Pathways. Biomed Res Int 2021;2021:4340950. [PMID: 34285910 DOI: 10.1155/2021/4340950] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 23 |
Shore ND, Palou Redorta J, Robert G, Hutson TE, Cesari R, Hariharan S, Rodríguez Faba Ó, Briganti A, Steinberg GD. Non-muscle-invasive bladder cancer: An overview of potential new treatment options. Urol Oncol 2021:S1078-1439(21)00221-0. [PMID: 34167873 DOI: 10.1016/j.urolonc.2021.05.015] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 24 |
Thomsen JA, Nielsen Dominiak H, Lindgren MS, Jensen JB. Adverse events of hyperthermic intravesical chemotherapy for non-muscle invasive bladder cancer patients. Scand J Urol 2021;55:281-6. [PMID: 34124993 DOI: 10.1080/21681805.2021.1938664] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 25 |
Lee JH, Kim B, Kim Y, Kim SK. Ultra-high rate of temperature increment from superparamagnetic nanoparticles for highly efficient hyperthermia. Sci Rep 2021;11:4969. [PMID: 33654131 DOI: 10.1038/s41598-021-84424-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 26 |
Wang S, Jin S, Shu Q, Wu S. Strategies to Get Drugs across Bladder Penetrating Barriers for Improving Bladder Cancer Therapy. Pharmaceutics 2021;13:166. [PMID: 33513793 DOI: 10.3390/pharmaceutics13020166] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 4.5] [Reference Citation Analysis]
|
| 27 |
Brummelhuis ISG, Wimper Y, Witjes-van Os HGJM, Arends TJH, van der Heijden AG, Witjes JA. Long-Term Experience with Radiofrequency-Induced Hyperthermia Combined with Intravesical Chemotherapy for Non-Muscle Invasive Bladder Cancer. Cancers (Basel) 2021;13:377. [PMID: 33498535 DOI: 10.3390/cancers13030377] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
|
| 28 |
van Valenberg FJP, Brummelhuis ISG, Lindner LH, Kuhnle F, Wedmann B, Schweizer P, Hossann M, Witjes JA, Oosterwijk E. DPPG2-Based Thermosensitive Liposomes with Encapsulated Doxorubicin Combined with Hyperthermia Lead to Higher Doxorubicin Concentrations in the Bladder Compared to Conventional Application in Pigs: A Rationale for the Treatment of Muscle-Invasive Bladder Cancer. Int J Nanomedicine 2021;16:75-88. [PMID: 33447028 DOI: 10.2147/IJN.S280034] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 29 |
Grimberg DC, Shah A, Tan WP, Etienne W, Spasojevic I, Inman BA. Hyperthermia Improves Solubility of Intravesical Chemotherapeutic Agents. BLC 2020;6:461-70. [DOI: 10.3233/blc-200350] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 30 |
Cao Y, Xu K, Chen B, Wang Y, Li B, Li C, Xu P. [Expression of DNMT3b in human bladder cancer tissue and its correlation with clinical prognosis]. Nan Fang Yi Ke Da Xue Xue Bao 2020;40:1295-300. [PMID: 32990224 DOI: 10.12122/j.issn.1673-4254.2020.09.11] [Reference Citation Analysis]
|
| 31 |
Di Gianfrancesco L, Ragonese M, Palermo G, Sacco E, Bassi P, Racioppi M. Second-Line Conservative Device-Assisted Intravesical Treatment in Selected Patients With Recurrent High-Risk Non-Muscle-Invasive Bladder Cancer. Clin Genitourin Cancer 2021;19:e100-19. [PMID: 33309565 DOI: 10.1016/j.clgc.2020.11.002] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 32 |
Chiancone F, Fabiano M, Fedelini M, Meccariello C, Carrino M, Fedelini P. Outcomes and complications of Hyperthermic IntraVesical Chemotherapy using mitomycin C or epirubicin for patients with non-muscle invasive bladder cancer after bacillus Calmette-Guérin treatment failure. Cent European J Urol 2020;73:287-94. [PMID: 33133655 DOI: 10.5173/ceju.2020.0148] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
|
| 33 |
Moussa M, Papatsoris AG, Dellis A, Abou Chakra M, Saad W. Novel anticancer therapy in BCG unresponsive non-muscle-invasive bladder cancer. Expert Rev Anticancer Ther 2020;20:965-83. [PMID: 32915676 DOI: 10.1080/14737140.2020.1822743] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
|
| 34 |
Tan WP, Chang A, Brousell SC, Grimberg DC, Fantony JJ, Longo TA, Etienne W, Spasojevic I, Maccarini P, Inman BA. Safety and efficacy of intravesical chemotherapy and hyperthermia in the bladder: results of a porcine study. Int J Hyperthermia 2020;37:854-60. [PMID: 32664768 DOI: 10.1080/02656736.2020.1780328] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
|
| 35 |
Grimberg DC, Shah A, Inman BA. Overview of Taris GemRIS, a Novel Drug Delivery System for Bladder Cancer. European Urology Focus 2020;6:620-2. [DOI: 10.1016/j.euf.2019.09.006] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
|
| 36 |
Huang J, Pu K. Near-infrared fluorescent molecular probes for imaging and diagnosis of nephro-urological diseases. Chem Sci 2020;12:3379-92. [PMID: 34163613 DOI: 10.1039/d0sc02925d] [Cited by in Crossref: 41] [Cited by in F6Publishing: 43] [Article Influence: 13.7] [Reference Citation Analysis]
|
| 37 |
Fankhauser CD, Teoh JY, Mostafid H. Treatment options and results of adjuvant treatment in nonmuscle-invasive bladder cancer (NMIBC) during the Bacillus Calmette–Guérin shortage: . Current Opinion in Urology 2020;30:365-9. [DOI: 10.1097/mou.0000000000000739] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 38 |
Leitemberger A, Sonego MS, Garcia FD, Dos Santos ACF, Piccoli BC, da Silva FD, Oliveira CS, Seixas FK, Dornelles L, Rocha JBT, Nogara PA, Schachtschneider KM, Collares T, Rodrigues OED. Synthesis and biological evaluation of new antioxidant and antiproliferative chalcogenobiotin derivatives for bladder carcinoma treatment. Bioorg Med Chem 2020;28:115423. [PMID: 32205047 DOI: 10.1016/j.bmc.2020.115423] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
|
| 39 |
Huang J, Jiang Y, Li J, He S, Huang J, Pu K. A Renal‐Clearable Macromolecular Reporter for Near‐Infrared Fluorescence Imaging of Bladder Cancer. Angew Chem 2020;132:4445-50. [DOI: 10.1002/ange.201911859] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
|
| 40 |
Liu K, Zhu J, Song YX, Wang X, Zhou KC, Lu Y, Liu XQ. Thermal Intravesical Chemotherapy Reduce Recurrence Rate for Non-muscle Invasive Bladder Cancer Patients: A Meta-Analysis. Front Oncol 2020;10:29. [PMID: 32117709 DOI: 10.3389/fonc.2020.00029] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
|
| 41 |
Huang J, Jiang Y, Li J, He S, Huang J, Pu K. A Renal-Clearable Macromolecular Reporter for Near-Infrared Fluorescence Imaging of Bladder Cancer. Angew Chem Int Ed Engl 2020;59:4415-20. [PMID: 31876017 DOI: 10.1002/anie.201911859] [Cited by in Crossref: 52] [Cited by in F6Publishing: 54] [Article Influence: 17.3] [Reference Citation Analysis]
|
| 42 |
Tan WP, Longo TA, Inman BA. Heated Intravesical Chemotherapy: Biology and Clinical Utility. Urol Clin North Am 2020;47:55-72. [PMID: 31757301 DOI: 10.1016/j.ucl.2019.09.008] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
|
| 43 |
Li X, Shu K, Zhou J, Yu Q, Cui S, Liu J, Zhou R, Ding D. Preoperative Plasma Fibrinogen and D-dimer as Prognostic Biomarkers for Non-Muscle-Invasive Bladder Cancer. Clin Genitourin Cancer 2020;18:11-19.e1. [PMID: 31787543 DOI: 10.1016/j.clgc.2019.10.025] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
|
| 44 |
Zhou J, Li L, Li X, Yu Q, Cui S, Shu K, Liu J, Liu J, Ding D, Du T. Efficacy analysis of a novel thermochemotherapy scheme with pirarubicin for intermediate- and high-risk nonmuscle-invasive bladder cancer: a single-institution nonrandomized concurrent controlled trial. International Journal of Hyperthermia 2019;36:867-74. [DOI: 10.1080/02656736.2019.1646929] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 45 |
Joice GA, Bivalacqua TJ, Kates M. Optimizing pharmacokinetics of intravesical chemotherapy for bladder cancer. Nat Rev Urol 2019;16:599-612. [PMID: 31434998 DOI: 10.1038/s41585-019-0220-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 4.8] [Reference Citation Analysis]
|
